首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Oropharyngeal administration of mother’s colostrum health outcomes of premature infants: study protocol for a randomized controlled trial
【2h】

Oropharyngeal administration of mother’s colostrum health outcomes of premature infants: study protocol for a randomized controlled trial

机译:母亲初乳的口咽给药早产儿的健康状况:一项随机对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

BackgroundExtremely premature (birth weight < 1250 g) infants are at high risk for acquiring late-onset sepsis and necrotizing enterocolitis, which are associated with significant mortality and morbidity. Own mother's milk contains protective (immune and trophic) biofactors which provide antimicrobial, anti-inflammatory, antioxidant, and immunomodulatory functions, enhance intestinal microbiota, and promote intestinal maturation. Many of these biofactors are most highly concentrated in the milk expressed by mothers of extremely premature infants. However, since extremely premature infants do not receive oral milk feeds until 32 weeks post-conceptional age, they lack the potential benefit provided by milk (biofactor) exposure to oropharyngeal immunocompetent cells, and this deficiency could contribute to late-onset sepsis and necrotizing enterocolitis. Therefore, oropharyngeal administration of own mother's milk may improve the health outcomes of these infants.
机译:背景极度早产(出生体重<1250 g)的婴儿罹患迟发性败血症和坏死性小肠结肠炎的风险很高,与显着的死亡率和发病率有关。自己的母乳含有保护性(免疫和营养性)生物因子,可提供抗微生物,抗炎,抗氧化和免疫调节功能,增强肠道菌群,并促进肠道成熟。这些生物因子中的许多都高度集中在极早产婴儿的母亲所分泌的牛奶中。但是,由于极早产的婴儿要到受孕后32周才接受口服乳汁喂养,因此他们缺乏牛奶(生物因子)接触口咽免疫功能细胞所提供的潜在益处,并且这种缺乏可能导致迟发性败血症和坏死性小肠结肠炎。因此,对自己的母乳进行口咽给药可能会改善这些婴儿的健康状况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号